Robert J. DelAversano net worth and biography

Robert DelAversano Biography and Net Worth

Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.
Prior to this appointment as OncoSec’s Principal Accounting Officer and Controller, Mr. DelAversano served as OncoSec’s Executive Director of Finance since 2018 where he had global responsibility for accounting, external financial reporting, and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, he was the Director of Financial Reporting and Taxation at Brio Financial Group (“Brio”), consulting with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw their accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services. In addition, he performed audit services, outsourced chief financial officer functions, and consulted clients through difficult Securities and Exchange Commission comment periods particularly through application of complex accounting principles for a large public company client base.

Mr. DelAversano holds a bachelor’s degree in Accounting from Rider University.

What is Robert J. DelAversano's net worth?: The estimated net worth of Robert J. DelAversano is at least $0.00 as of February 9th, 2023. Mr. DelAversano owns 1,008 shares of OncoSec Medical stock worth more than $0 as of April 26th. This net worth approximation does not reflect any other assets that Mr. DelAversano may own. Learn More about Robert J. DelAversano's net worth.
How do I contact Robert J. DelAversano?: The corporate mailing address for Mr. DelAversano and other OncoSec Medical executives is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. OncoSec Medical can also be reached via phone at (855) 662-6732 and via email at [email protected]. Learn More on Robert J. DelAversano's contact information.
Has Robert J. DelAversano been buying or selling shares of OncoSec Medical?: Robert J. DelAversano has not been actively trading shares of OncoSec Medical in the last ninety days. Most recently, Robert J. Delaversano sold 40 shares of the business's stock in a transaction on Thursday, February 9th. The shares were sold at an average price of $1.37, for a transaction totalling $54.80. Following the completion of the sale, the vice president now directly owns 1,008 shares of the company's stock, valued at $1,380.96. Learn More on Robert J. DelAversano's trading history.
Who are OncoSec Medical's active insiders?: OncoSec Medical's insider roster includes Robert DelAversano (VP), Brian Leuthner (CEO), Daniel O'Connor (CEO), and Yuhang Zhao (Director). Learn More on OncoSec Medical's active insiders.

Robert J. DelAversano Insider Trading History at OncoSec Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/9/2023	Sell	40	$1.37	$54.80	1,008
11/4/2022	Sell	283	$0.37	$104.71	22,975
8/5/2022	Sell	284	$0.71	$201.64	23,258
5/6/2022	Sell	274	$0.83	$227.42	23,542
2/9/2022	Sell	409	$0.88	$359.92
11/1/2021	Sell	343	$1.75	$600.25
8/2/2021	Sell	412	$2.18	$898.16	24,568
5/3/2021	Sell	453	$4.86	$2,201.58	24,980

Robert J. DelAversano Buying and Selling Activity at OncoSec Medical

OncoSec Medical Company Overview

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Today's Range

Now: N/A

50 Day Range

MA: $0.52

$0.20

$0.94

2 Week Range

Now: N/A

Volume

52,491,000 shs

Average Volume

2,219,449 shs

Market Capitalization

$1.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy